Document is current

Article History

Accepted: 17 November 2024

First Online: 6 January 2025

Declarations

:

: This study was funded by Incyte Corporation (Wilmington, DE, USA).

: LSG has served as an investigator, advisor, and/or speaker for AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Ortho Dermatologics, Pfizer, Regeneron, and Sanofi. RB is an advisory board member, consultant, speaker, and/or investigator for and received honoraria and/or grants from AbbVie, Almirall, Amgen, AnaptysBio, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Escalier, Janssen, Kyowa Kirin, LEO Pharma, Nimbus, Pfizer, Regeneron, Sienna, and UCB. He is also an employee and shareholder of Innovaderm Research. SF has received honoraria, clinical research grants, or fees as a consultant, speaker, advisory board member, and/or investigator for AbbVie, Aclaris Therapeutics, Asana BioSciences, AstraZeneca, Athenex, Celgene Corporation, Cutanea Life Sciences, Eli Lilly, Incyte Corporation, Innovaderm Research, Novartis, Pfizer, Promius Pharma, Regeneron, UCB, Valeant Pharmaceuticals North America, and XBiotech. AZ has served as an investigator and/or consultant for AbbVie, Biofrontera, Dermavant, Galderma, Incyte, and UCB. YK, BA, XC, and HK are employees and shareholders of Incyte Corporation. ASP has served as an investigator, consultant, or data safety monitoring board member for AbbVie, Abeona, Apogee, Applied Pharma Research, Arcutis, Aslan, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, Johnson and Johnson, Krystal Biotech, LEO, Mitsubishi Tanabe, Nektar, Primus, Procter and Gamble, Regeneron, Sanofi, Seanergy, TWI Biotech, and UCB. ASP is an editorial board member of the American Journal of Clinical Dermatology. ASP was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except Phase 1 studies) for which the product and indication have been approved on or after 1 January 2020 in at least one major market (e.g., US, EU, JPN). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte’s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: .

: This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was approved by the Advarra Institutional Review Board (Columbia, MD, USA).

: Written informed consent/assent was provided by all patients before enrollment.

: Not applicable.

: Not applicable.

: LSG, RB, BA, HK, and ASP made substantial contributions to the conception and design of the work. LSG, RB, SF, AZ, and ASP all made substantial contributions to the acquisition of data. YK and XC made substantial contributions to the analysis of the data; all authors made substantial contributions to the interpretation of data; all authors drafted the work and revised it critically for important intellectual content, approved the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.